HBV Amplification Oligomer Composition for Multi-Genotype Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid-based detection and quantification methods for Hepatitis B Virus (HBV) are complicated by genetic heterogeneity and error-prone replication, leading to inaccurate and insensitive detection across multiple genotypes and subtypes, particularly at low concentrations.
Innovation Solution
A composition comprising multiple amplification oligomers with specific target-hybridizing sequences, including first, second, third, and fourth amplification oligomers, each targeting distinct HBV sequences, along with optional promoter-primers and non-nucleotide detectable labels, to enhance detection and quantification accuracy and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a small set of amplification oligomers and probes is used, then the assay is simple and resource-efficient, but detection reliability and sensitivity deteriorate due to inability to reliably detect multiple genotypes
Solution Approach 1:
The patent divides the detection system into multiple specialized amplification oligomers, each designed to target specific HBV genotypes or genotype groups. This segmentation allows each oligomer to be optimized for its specific target while collectively covering all known genotypes, resolving the contradiction between simplicity and reliability.
Solution Approach 2:
The patent creates a universal detection system where a single assay platform can detect all HBV genotypes by incorporating multiple amplification oligomers with different target sequences. This multi-functionality allows the same assay to reliably detect diverse genotypes without requiring separate tests for each genotype.
2Reliability
If multiple amplification oligomers are used to detect all genotypes, then detection reliability improves, but assay complexity and potential for false negatives increase due to oligomer interactions and resource competition
Solution Approach 1:
The patent applies local quality by designing each amplification oligomer with specific characteristics optimized for its target genotype, such as specific binding affinities and amplification efficiencies. This allows each component to perform its function optimally while minimizing interference with other oligomers, reducing false negatives.
Solution Approach 2:
The patent incorporates preliminary actions by including control oligomers and probes that are pre-designed to detect amplification failures and genotype-specific variations before they can lead to false negatives. This preliminary detection of potential issues ensures reliable results even when multiple oligomers are used simultaneously.
3Adaptability or versatility
If standard nucleic acid assays are used, then the method is widely applicable, but measurement precision deteriorates due to genetic heterogeneity and error-prone replication
Solution Approach 1:
The patent introduces dynamic adaptation by allowing the amplification oligomers to be selected or adjusted based on the specific genotype or genotype group being detected. This dynamic approach enables the assay to optimize its parameters for each genotype, maintaining high measurement precision across all HBV genotypes while preserving broad applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides sensitive and specific detection and quantification of HBV across various genotypes, reducing false negatives and improving accuracy, especially at low concentrations.
Implementation Method 1
the first amplification oligomer comprises a target-hybridizing sequence comprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 2 or 3; the second amplification oligomer comprises a target-hybridizing sequence comprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 20, 21, or 22
Implementation Method 2
performing a nucleic acid amplification reaction in the composition which produces at least first and second amplicons in the presence of a Hepatitis B virus nucleic acid
Data Source
AI summary
This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis B virus (HBV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the P and/or S open reading frames of HBV and are configured to provide substantially equivalent quantification of different genotypes and variants of HBV.